Cargando…
Goserelin Ovarian Ablation Failure in Premenopausal Women With Breast Cancer
Breast cancer is the most prevalent cancer known worldwide in women. It is a heterogeneous, phenotypically diverse disease composed of several biologic subtypes that have distinct behavior and response to therapy. Hormone receptor-positive (i.e., estrogen [ER] and/or progesterone [PR] receptor-posit...
Autores principales: | Gupta, Aanchal, Bandaru, Sindhura, Manthri, Sukesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674405/ https://www.ncbi.nlm.nih.gov/pubmed/34956746 http://dx.doi.org/10.7759/cureus.19608 |
Ejemplares similares
-
The Rarest of the Rare: A Case of BAP1-Mutated Primary Peritoneal Mesothelioma
por: Gupta, Aanchal, et al.
Publicado: (2021) -
Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
por: Hackshaw, Allan, et al.
Publicado: (2009) -
Long-time Response with Ado-trastuzumab Emtansine in a Recurrent Metastatic Breast Cancer
por: Manthri, Sukesh, et al.
Publicado: (2019) -
Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
por: Dixon, A. R., et al.
Publicado: (1990) -
Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)